Oral Minoxidil Pharmacogenomics: Why Genetics Shape Your Response

What Does SULT1A1 Have to Do With Minoxidil?

Minoxidil is converted to minoxidil sulfate through sulfotransferase activity. SULT1A1 is an enzyme involved in this activation, and its activity can be measured in plucked scalp hair follicles [1,2]. That biochemical relationship makes it a reasonable subject for research into treatment response.

Three different questions must remain separate: whether a person carries a DNA variant, how much enzyme activity is measured in a particular sample, and whether their hair improves with a particular treatment. A finding about one does not automatically settle the others.

The route of treatment matters too. A study designed to predict topical minoxidil response is not an oral-minoxidil dosing study. The two treatments have different exposure conditions, even though they share an active ingredient.

What the Preliminary Topical Assay Study Found

Goren and colleagues described a preliminary retrospective study of a follicular SULT1A1 activity assay. It reported 95% sensitivity and 73% specificity for predicting response to topical minoxidil in androgenetic alopecia [1]. These values describe the performance of that assay in the study, not the probability that an individual patient will grow hair.

The authors described a larger prospective study as the next validation step. Independent prospective validation matters before an assay result is used to guide a general prescribing rule.

The paper's introductory estimate of 30-40% efficacy also concerns topical treatment. It is not evidence that genetics explains a 30-40% nonresponse rate among all patients taking oral minoxidil. Response definitions, treatment duration and patient selection affect such percentages.

What Was Observed With Oral Minoxidil?

A 2024 study evaluated 41 patients with androgenetic alopecia receiving low-dose oral minoxidil for six months. The investigators measured sulfotransferase activity in plucked scalp hair follicles and compared clinical response between activity groups [2].

The reported response rate was higher in the low-activity group than in the high-activity group, 85% versus 43%, with a reported P value of 0.009. That direction differs from the simple assumption that higher follicular activity always predicts a better minoxidil response.

This was a small study. It did not establish an ancestry-specific starting dose, a validated genotype dosing algorithm, or a guaranteed benefit from switching a topical nonresponder to oral treatment. Its conclusion supports further investigation of the mechanism and patient selection.

A proposed explanation involving activation outside the scalp remains different from proof that a particular patient's liver will compensate for low follicular activity. An enzyme result alone does not justify promising a response at 2.5 mg or a higher dose.

Is an Enzyme Assay the Same as a Genetic Test?

No. A follicular activity assay measures what an enzyme does in the sampled material. Genotyping identifies a DNA sequence or variant. Neither measurement is interchangeable with the other, and a result needs to be interpreted for the actual treatment studied [1-3].

When considering a test, identify the sample, measurement, intended treatment route and validation population. Ask whether it predicts topical response, oral response or neither. A general pharmacogenomic panel should not be assumed to include SULT1A1 or to provide a validated minoxidil prescription.

The cited research does not establish a universal test price, insurer benefit or savings from testing before treatment. Those practical claims would need evidence about the actual test and program, rather than a price assigned to pharmacogenomics in general.

Do Ancestry or Allele Frequencies Determine the Dose?

A study by Carlini and colleagues compared SULT1A1 and SULT1A2 allele frequencies in three study populations [3]. It documented variation in allele frequencies and described the work as a step toward understanding potential functional implications for sulfate conjugation.

It did not test an oral-minoxidil prescribing strategy. Population frequencies cannot identify which alleles an individual carries, directly measure that individual's enzyme activity, or establish the dose most likely to help them.

The study therefore does not support starting people of one ancestry at a higher dose than people of another. A population comparison should not become a prescription table without treatment-specific clinical validation.

Other Genes: Hair-Loss Risk Is Not Drug-Response Prediction

Genetic studies can investigate androgenetic alopecia itself. Hagenaars and colleagues identified more than 250 independent genetic loci associated with severe hair loss in a study of more than 52,000 men [4]. That was research on hair-loss risk, not a trial assigning oral-minoxidil doses according to a genetic panel.

A gene involved in hair-loss susceptibility may be biologically relevant without being a validated predictor of drug response. The same distinction applies when proposing a combination treatment: a risk marker alone does not establish that a particular patient needs finasteride or dutasteride in addition to minoxidil.

For research about potassium channels or rare syndromes, check the actual population and outcome. A rare-variant mechanism or laboratory experiment does not, by itself, provide a dose conversion for common variants in ordinary hair-loss care.

How Should Treatment Decisions Be Made Today?

The international modified Delphi consensus on low-dose oral minoxidil addresses clinical prescribing questions such as diagnosis, patient selection, starting doses, baseline evaluation and monitoring. It is expert consensus, rather than a genotype-stratified treatment trial [5].

There is no validated SULT1A1 table in the studies cited here that assigns 1.25 mg to one genotype, 2.5 mg to another and 5 mg to a third. Nor do these studies establish that a test result should automatically trigger an additional hair-loss medication.

Treatment response should be assessed using the actual diagnosis and regimen. Comparable photographs, the treatment duration and a record of use are more informative than interpreting a DNA result as a guarantee. If response is incomplete, review those clinical details before attributing the outcome to a presumed genetic ceiling.